About Zinc finger protein 134
Zinc finger protein 134 (ZNF134) is a protein
from Homo sapiens identified by UniProt accession
P52741, 427 residues long.
MolForge cross-references it against 0 known binders and
11 disease associations.
Target properties
| Protein name | Zinc finger protein 134 |
| UniProt accession | P52741 |
| Gene | ZNF134 |
| Organism | Homo sapiens |
| Length | 427 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (11)
Diseases linked to this target (Open Targets).
- Mastocytosis · score 0.25
- Red cell distribution width · score 0.04
- platelet component distribution width · score 0.02
- diffuse large B-cell lymphoma · score 0.01
- microphthalmia with limb anomalies · score 0.01
- oral squamous cell carcinoma · score 0.00
- osteoarthritis · score 0.00
- activated PI3K-delta syndrome · score 0.00
- type 2 diabetes mellitus · score 0.00
- breast carcinoma · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P52741-F1 | alphafold | PREDICTED | 65.39 | — |
Amino-acid sequence (427 residues)
MTLVTAGGAW TGPGCWHEVK DEESSSEQSI SIAVSHVNTS KAGLPAQTAL PCDICGPILK DILHLDEHQG THHGLKLHTC GACGRQFWFS ANLHQYQKCY SIEQPLRRDK SEASIVKNCT VSKEPHPSEK PFTCKEEQKN FQATLGGCQQ KAIHSKRKTH RSTESGDAFH GEQMHYKCSE CGKAFSRKDT LVQHQRIHSG EKPYECSECG KAFSRKATLV QHQRIHTGER PYECSECGKT FSRKDNLTQH KRIHTGEMPY KCNECGKYFS HHSNLIVHQR VHNGARPYKC SDCGKVFRHK STLVQHESIH TGENPYDCSD CGKSFGHKYT LIKHQRIHTE SKPFECIECG KFFSRSSDYI AHQRVHTGER PFVCSKCGKD FIRTSHLVRH QRVHTGERPY ECSECGKAYS LSSHLNRHQK VHTAGRL
Explore Zinc finger protein 134 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets